Iberdomide FDA PDUFA review: first-in-class CELMoD for multiple myeloma

The U.S. Food and Drug Administration (FDA) is completing its review of Bristol Myers Squibb's (BMS) New Drug Application (NDA) for iberdomide (investigational development code CC-220), an oral, first-in-class cereblon E3 ligase modulator (CELMoD). The application seeks commercial approval for iberdomide in combination with subcutaneous daratumumab and dexamethasone (the IberDd regimen) for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy, including prior lenalidomide exposure.

The FDA accepted the NDA on February 17, 2026, granting Breakthrough Therapy Designation and Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of August 17, 2026. As of August 7, 2026, iberdomide remains under active FDA review without a public decision announcement. If approved, iberdomide would become the pioneer asset in the CELMoD class, establishing a distinct pharmacologic modality engineered to succeed the legacy IMiD backbone—lenalidomide (Revlimid), pomalidomide (Pomalyst), and thalidomide (Thalomid)—that has anchored myeloma care for over twenty years.

This comprehensive regulatory and clinical review provides a pre-approval decision framework for hematologists, GI/oncology clinical specialists, hospital pharmacy directors, and PBM specialty P&T committees. It evaluates the pivotal trial evidence, surrogate endpoint validity, structural chemistry, long-term FAERS safety surveillance across predecessor IMiDs, and practical access logistics ahead of the FDA's PDUFA deadline.

---

Executive Summary & PDUFA Fact Sheet

---

What is iberdomide and how do CELMoDs differ from IMiDs?

While both traditional immunomodulatory drugs (IMiDs) and novel CELMoDs bind the cereblon (CRBN) subunit of the CRL4-CRBN E3 ubiquitin ligase complex, iberdomide was synthetically optimized using computer-aided structural design to achieve significantly tighter binding kinetics and altered structural recruitment.

       IMiD (Lenalidomide / Pomalidomide) vs. CELMoD (Iberdomide) Binding Axis
       ======================================================================

   [Cereblon (CRBN)] <--- Moderate K_d (Micromolar) ---> [IKZF1 / IKZF3 Substrates]
          |                                                    |
          +--> Suboptimal degradation in CRBN-low cells -------+

   --------------------------------------------------------------------------

   [Cereblon (CRBN)] <--- High K_d (Nanomolar, ~20x) ---> [IKZF1 / IKZF3 Substrates]
          |                                                    |
          +--> Rapid, complete degradation in IMiD resistance -+

Key Mechanistic Advances

1. Substrate Degradation Kinetics: Iberdomide induces rapid, deep degradation of the essential ikaros (IKZF1) and aiolos (IKZF3) zinc-finger transcription factors at nanomolar concentrations. Downstream depletion of IKZF1 and IKZF3 triggers immediate transcriptional repression of IRF4 and MYC, driving apoptotic cell death in plasma cells.
2. Activity in IMiD-Resistant Disease: In myeloma cells that have developed clinical resistance to lenalidomide or pomalidomide—frequently mediated by reduced CRBN expression levels or altered co-factor binding—iberdomide retains potent degradation capability due to its >20-fold higher binding affinity for cereblon.
3. Potent Immune Effector Co-Stimulation: Beyond direct myeloma cell cytotoxicity, iberdomide stimulates co-stimulatory cytokine release (IL-2 and IFN-gamma) in T cells and natural killer (NK) cells. This immune activation enhances antibody-dependent cellular cytotoxicity (ADCC) when combined with targeted monoclonal antibodies such as daratumumab.

Structural Comparison: IMiDs vs. CELMoDs

---

What did the EXCALIBER-RRMM trial show?

The NDA submission for the IberDd regimen relies primarily on efficacy and safety data from the international, randomized Phase 3 EXCALIBER-RRMM trial (NCT04975997; design and methods published by Lonial et al., Future Oncol 2025, PMC12150652 / PMID 40346992). EXCALIBER-RRMM is a two-stage, open-label study. Stage 1 performed dose optimization and selected 1.0 mg iberdomide as the recommended dose; Stage 2 randomized approximately 664 patients with relapsed or refractory multiple myeloma (1 to 2 prior lines, including lenalidomide) 1:1 to IberDd or to daratumumab + bortezomib + dexamethasone (DVd).

                      EXCALIBER-RRMM Phase 3 Trial Architecture
                      =========================================

  RRMM Patients (1-2 Prior Lines, including Lenalidomide Exposure)
                           |
                           +---> Arm A: IberDd (Iberdomide + SC Daratumumab + Dex)
                           |     -> Co-Primary Endpoint: MRD Negativity Rate at 10⁻⁵
                           |     -> Co-Primary Endpoint: Progression-Free Survival (PFS)
                           |
                           +---> Arm B: Control (DVd: Daratumumab + Bortezomib + Dex)

Clinical Efficacy: What Has Been Disclosed

The filing is supported by a planned interim analysis demonstrating that IberDd produced a statistically significant improvement in minimal residual disease (MRD) negativity rates at 10⁻⁵ sensitivity compared with DVd in lenalidomide-exposed RRMM patients. This MRD result is the efficacy basis BMS put before the FDA under Breakthrough Therapy Designation and Priority Review.

Several points are important for formulary and evidence committees weighing the filing:

• Dual primary endpoints: EXCALIBER-RRMM was designed with MRD negativity and progression-free survival (PFS) as co-primary endpoints. The current submission rests on the MRD analysis; PFS data are still maturing and the trial remains ongoing.
• Detailed Phase 3 numerics are not yet public: Specific Phase 3 ORR, PFS, and depth-of-response figures have not been disclosed in the public materials underpinning this NDA. Preliminary single-agent and combination activity was previously reported in the heavily pretreated CC-220-MM-001 Phase 1/2 population (Lonial et al., Lancet Haematol 2022), which showed manageable safety and early efficacy including in IMiD- and daratumumab-refractory disease, but those Phase 1/2 numbers should not be read as the Phase 3 registrational result.
• Why MRD matters here: MRD negativity correlates with prolonged PFS and OS in myeloma, but it is a surrogate endpoint. An approval resting on MRD — before mature PFS — would be a notable regulatory precedent for oral oncology therapies.

The MRD Regulatory Precedent

A major focal point for pharmacy directors and P&T committees is BMS's use of MRD negativity at 10⁻⁵ as the efficacy basis for Priority Review while the co-primary PFS endpoint continues to mature. MRD negativity is a recognized but still surrogate endpoint in myeloma; following prior FDA Oncologic Drugs Advisory Committee discussions of surrogate endpoints in hematologic malignancies, an iberdomide approval resting on MRD would set an important precedent for accelerating access to next-generation oral oncology therapies — and would place post-marketing obligations on confirmatory PFS and overall survival readouts.

---

Where does iberdomide fit in the RRMM treatment sequence?

The clinical sequencing of relapsed multiple myeloma has become increasingly intricate following the introduction of anti-CD38 monoclonal antibodies (daratumumab, isatuximab), BCMA-targeted bispecifics (teclistamab, elranatamab), GPRC5D bispecifics (talquetamab), and CAR-T therapies (idecabtagene vicleucel, ciltacabtagene autoleucel).

                 Relapsed/Refractory Multiple Myeloma Sequencing Ladder
                 =====================================================

   1st Line (1L)            2nd / 3rd Line (2L-3L)              4th Line+ (4L+)
   --------------          ------------------------            -----------------
   VRd / DRd Quadruplet -> IberDd (Iberdomide + Dara SC) ---> BCMA/GPRC5D Bispecifics
                           (Oral CELMoD Backbone)             (Teclistamab / Talquetamab)
                           *Targeting IMiD Refractory*         or CAR-T (Carvykti / Abecma)

Comparative Modality Matrix: IberDd vs. Competitor Regimens

Strategic Clinical Positioning

1. Second-Line (2L) Post-Lenalidomide Progression: Most multiple myeloma patients in the U.S. receive VRd (bortezomib/lenalidomide/dex) or DRd quadruplets in the front-line setting and progress on lenalidomide maintenance. IberDd provides an immediate oral transition option that avoids switching to infused chemotherapy.
2. Outpatient Pre-T-Cell Redirection Bridge: Unlike bispecific antibodies (TCEs) that mandate inpatient step-up monitoring for cytokine release syndrome (CRS), IberDd is administered entirely in the outpatient clinic setting.
3. Synergy with Established SC Infrastructure: Iberdomide is formulated to pair with subcutaneous daratumumab (Darzalex Faspro). Clinics already equipped for SC daratumumab administration can add iberdomide without increasing chair time. Review our daratumumab SC vs IV tracker for formulation logistics.
4. BMS Portfolio Positioning: For broader context on how BMS is managing portfolio transitions ahead of patent cliffs, see our BMS portfolio dossier.

---

What is the IMiD-class safety baseline iberdomide enters?

To establish the safety landscape into which iberdomide will launch, we evaluate post-marketing adverse event data from the FDA Adverse Event Reporting System (FAERS) for reports received between 2018 and 2026 across predecessor IMiDs: lenalidomide, pomalidomide, and thalidomide.

Cumulative IMiD Class FAERS Safety Benchmark (2018–2026)

Across the 2018–2026 surveillance window, the FDA database accumulated 321,848 any-role adverse event reports referencing the three commercial IMiD substances.

       IMiD Class FAERS Adverse Event Distribution (321,848 Any-Role Reports, 2018–2026)
       =================================================================================

       Lenalidomide  [#################################################] 250,226 (77.7%)
       Pomalidomide  [#############] 68,561 (21.3%)
       Thalidomide   [##] 9,376 (2.9%)

       *Per-substance counts reflect individual drug mentions and are non-additive.*

Reporting-Trend Context

IMiD reporting volume peaked around 2021 and has declined since, consistent with lenalidomide generic entry (Revlimid loss of exclusivity in early 2022) and the usual FAERS reporting lag for the most recent years. These counts reflect any drug mention in a report (a report may list several drugs), so the per-substance totals are non-additive; they quantify the surveillance burden and class safety signal rather than causal incidence.

Adverse Event Management: IMiDs vs. Expected Iberdomide Profile

1. Neutropenia & Hematologic Toxicity: Neutropenia and other cytopenias are class effects of IMiDs and CELMoDs and were a central driver of Stage-1 dose optimization, which selected 1.0 mg as the recommended Phase 3 dose. Expect routine blood-count monitoring during Cycle 1 and protocolized dose modifications for hematologic toxicity.
2. Venous Thromboembolism (VTE) Risk: Like lenalidomide and pomalidomide, iberdomide increases VTE risk when combined with dexamethasone. Mandatory thromboprophylaxis (aspirin 81–325 mg daily for low risk; LMWH or direct oral anticoagulants like apixaban for high risk) must be prescribed.
3. Teratogenicity & Reproductive Safety: Structural homology to thalidomide dictates that iberdomide carries severe embryo-fetal risk, requiring a mandatory REMS program.
4. Second Primary Malignancies (SPMs): Long-term surveillance for secondary hematologic or solid tumor malignancies will be required post-marketing, echoing lenalidomide safety requirements.

---

REMS, Monitoring, and Payer Access Considerations

If approved on August 17, 2026, iberdomide's commercial integration will require coordinated execution across specialty pharmacy networks, REMS compliance, and PBM benefit design.

                 Iberdomide Commercial & Access Flow Architecture
                 ===============================================

   [FDA Approval (Aug 17)] ---> [REMS Program Rollout] ---> [Specialty Pharmacy Network]
                                       |                                  |
                                       v                                  v
                            Mandatory Prescriber /            Dual-Channel Coverage:
                            Pharmacy Certification            - Iberdomide (Part D / Pharmacy)
                            & Patient Agreement               - SC Daratumumab (Part B / Medical)

1. Risk Evaluation and Mitigation Strategy (REMS)

Iberdomide will launch under a strict REMS program modeled after the Revlimid/Pomalyst REMS. Key compliance requirements:

• Mandatory registration and annual recertification of prescribers and dispensing specialty pharmacies.
• Mandatory negative pregnancy tests for females of reproductive potential prior to initiating each 28-day cycle.
• Generation of a unique REMS confirmation authorization code before specialty pharmacies can dispense shipments.

2. Payer Benefit Design & Prior Authorization (PA)

Because IberDd pairs an oral capsule (iberdomide) with a clinic-administered subcutaneous injection (daratumumab), coverage will cross channels:

• Pharmacy Benefit (Part D): Iberdomide will route through Medicare Part D / commercial specialty pharmacy channels, placed on Tier 5 (Specialty) with 25–33% coinsurance. Prior authorization will require proof of RRMM after ≥1 prior line including lenalidomide.
• Medical Benefit (Part B): Subcutaneous daratumumab (Darzalex Faspro) bills under HCPCS code J9144 (injection, daratumumab and hyaluronidase-fihj, 10 mg); intravenous daratumumab uses J9145. No daratumumab biosimilar is FDA-approved as of August 2026.
• Bridge Programs: BMS is expected to offer co-pay assistance cards for commercial patients and a temporary free-trial bridge program for patients experiencing PBM prior authorization delays.

3. Hospital & Clinical Pharmacy Action Items

• Formulary Placement: P&T committees should establish temporary restricted-use criteria for IberDd in lenalidomide-refractory RRMM pending final PDUFA approval.
• Order Set Integration: EHR order sets (Epic Beacon / Cerner Millennium) must embed mandatory thromboprophylaxis and ANC monitoring parameters into the IberDd regimen template.
• Specialty Pharmacy Dispensing Logistics: Ensure specialty pharmacy teams complete BMS REMS system integration prior to the expected commercial launch date.

---

Frequently Asked Questions (FAQ)

When is the FDA decision date for iberdomide in multiple myeloma?

The FDA PDUFA target action date for iberdomide is August 17, 2026.

Is iberdomide currently approved by the FDA?

No. As of August 7, 2026, iberdomide is an investigational agent under active Priority Review by the FDA. Approval is pending the agency's final determination.

Will iberdomide require a REMS program like lenalidomide?

Yes. Due to its structural relationship to thalidomide, iberdomide is expected to require a mandatory pregnancy-prevention REMS program for prescribers, specialty pharmacies, and patients.

---

Sources

1. Bristol Myers Squibb: U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma. Corporate Press Release, February 17, 2026. https://news.bms.com/news/corporate-financial/2026/U-S--Food-and-Drug-Administration-Accepts-Bristol-Myers-Squibbs-New-Drug-Application-for-Iberdomide-in-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma/default.aspx
2. ClinicalTrials.gov: A Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib and Dexamethasone (DVd) or Daratumumab, Lenalidomide and Dexamethasone (DRd) in Patients With Relapsed or Refractory Multiple Myeloma (EXCALIBER-RRMM). NCT04975997. https://clinicaltrials.gov/study/NCT04975997
3. PubMed Central (PMC): Lonial S, Dimopoulos MA, Berdeja JG, et al. EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma. Future Oncol. 2025;21(14):1761-1769. PMC12150652 (PMID 40346992). https://pmc.ncbi.nlm.nih.gov/articles/PMC12150652
4. CancerNetwork: Will the FDA Approve Iberdomide in Relapsed/Refractory Multiple Myeloma? Expert Commentary & PDUFA Analysis, 2026. https://www.cancernetwork.com/view/will-the-fda-approve-iberdomide-in-relapsed-refractory-multiple-myeloma-
5. U.S. Food and Drug Administration: FDA Adverse Event Reporting System (FAERS) Public Data Set. Post-Marketing Safety Reports for Lenalidomide, Pomalidomide, and Thalidomide (2018–2026 Surveillance Cohort). https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers